Print Page     Close Window     

SEC Filings

8-K
SERES THERAPEUTICS, INC. filed this Form 8-K on 11/08/2018
Entire Document
 


SERES THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited, in thousands, except share and per share data)

 

     Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
     2018     2017     2018     2017  

Revenue:

        

Collaboration revenue - related party

   $ 8,684     $ 23,015     $ 16,721     $ 29,044  

Grant revenue

     371       —         917       —    
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     9,055       23,015       17,638       29,044  

Operating expenses:

        

Research and development expenses

     23,675       22,210       71,188       65,413  

General and administrative expenses

     7,591       8,119       25,063       25,251  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     31,266       30,329       96,251       90,664  
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss from operations

     (22,211     (7,314     (78,613     (61,620
  

 

 

   

 

 

   

 

 

   

 

 

 

Other income (expense):

        

Interest income (expense), net

     262       379       958       1,193  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other income (expense), net

     262       379       958       1,193  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

   $ (21,949   $ (6,935   $ (77,655   $ (60,427
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share attributable to common stockholders, basic and diluted

   $ (0.54   $ (0.17   $ (1.91   $ (1.49
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average common shares outstanding, basic and diluted

     40,806,413       40,494,049       40,699,422       40,419,522  
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income:

        

Unrealized gain on investments, net of tax of $0

   $ 20     $ 77     $ 137     $ 50  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other comprehensive income

     20       77       137       50  
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive loss

   $ (21,929   $ (6,858   $ (77,518   $ (60,377
  

 

 

   

 

 

   

 

 

   

 

 

 

IR or PR Contact:

Carlo Tanzi, Ph.D., Seres Therapeutics, 617-203-3467

Vice President, Investor Relations and Corporate Communications

ctanzi@serestherapeutics.com

###


© Seres Therapeutics. All Rights Reserved.